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Objectives: Review of the design of a clinical study to evaluate of the efficacy of epidural spinal cord electrical stimulation 
(ESES) as compared to best medical treatment in patients with nonreconstructible critical imb ischaemia. 
Design. Randomised controlled clinical trial of pragmatic type, which will be analysed according to the intention-to-treat 
principle. The treatment s rategies are ESES, in addition to best medical treatment, and best medical treatment alone. 
Patients are followed-up for at least 18 months. 
Setting: The ESES-trial is an ongoing multicentre trial in 17 hospitals in The Netherlands. 
Patients, Patients with critical imb ischaemia, nonsuitable for either primary intervention orreintervention after failing 
reconstructions. 
Chief outcome measures: Limb survival, patient survival, quality of life and cost-effectiveness. 
Main results: From November 1991 until May 1994 120 patients had been enrolled. Using life-table analysis, at one year 
76% of these randomised patients were alive: 41% without amputation and 35% with amputation. Quality of life of the 
trial patients was low, even compared to other severely ill patient groups, such as liver and heart ransplant candidates. 
Conclusions: Considering the high incidence of death and amputation, 18 months of follow-up seems adequate odetect 
a clinically relevant outcome improvement from ESES-treatment, if present. We hope to present the results of this study 
at the end of 1995. 
Key Words: Clinical trial; Randomised controlled trial; Critical imb ischaemia; Spinal cord stimulation; Arterial occlusive 
disease; Quality of life; Pain; Cost analysis; Analgesia. 
Introduction 
Chronic critical limb ischaemia has an unfavourable 
natural history, leading to amputation of the limb in 
60-80% of patients within a year. 1-a Surgical bypass or 
endovascular procedures are the treatment of choice. 
Despite major advances in limb salvage by vascular 
repair, there remain patients who are unsuitable for 
either primary intervention or reintervention after 
failed reconstructions. Until recently, treatment of 
such patients was restricted to medical treatment: 
analgesics for ischaemic pain, haemorrheologic medi- 
cation to enhance the (micro)circulation and local 
wound care for ischaemic skin lesions. 4~ Ultimately 
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however, many of these patients face major lower- 
extremity amputation, which bears a high risk of 
disabilit~ prolonged hospitalisation and death. 
Epidural spinal cord electrical stimulation (ESES) 
activates the dorsal columns of the spinal cord and 
causes paresthesias in the lower extremity, alleviating 
pain of various origins. 9Moreover, ulcer healing and 
10 therefore a limbsaving effect has been suggested. A 
number of studies have been carried out to evaluate 
the use of ESES for ischaemia of the leg, leading to 
enthusiastic recommendation of this treatment. 11-19 
One year limb salvage was reported to be approx- 
imately 80%, two year limb survival about 
50%. 16"17'20-22 These studies were uncontrolled or 
made historical comparisons and a randomised con- 
trolled clinical trial was clearly required. In this paper, 
we describe the design issues of the ESES-trial in The 
Netherlands. 
1078-5884/95/080478 + 08 $12.00/0 © 1995 W. B. Saunders Company Ltd. 
Trial SCS in Critical Limb Ischaemia 479 
Design 
The study is designed as a randomised controlled 
clinical trial. The treatment strategies are best medical 
treatment alone (standard treatment) versus best 
medical treatment plus ESES (ESES-treatment), and 
these are allocated at random to patients that meet the 
inclusion criteria. The eligibility criteria are shown in 
Table 1. Seventeen centres collaborated in the study. 
Patient data are collected on standardised patient- 
record forms. The aim is to compare "ESES-treatment" 
with "standard treatment", in patients with non- 
reconstructible critical ischaemia of one leg. Both 
treatments will be analysed with regard to limb 
survival, patient survival, quality of life and cost- 
effectiveness. Quality of life is measured by a generic 
questionnaire (Nottingham Health Profile) and dis- 
ease-specific questionnaires for mobility and pain. The 
costs of the alternative treatments will be compared by 
means of an economic evaluation. We use real cost 
rather than reimbursement fees. The secondary out- 
come measures are: use of analgesics, healing of 
ischaemic skin lesions, amputation level, complica- 
tions, and macro- and microcirculatory measurements 
Table 1. ESES-trial eligibility criteria 
Inclusion criteria: 
Critical ischaemia ofone of the lower limbs in patients, for whom a 
meaningful vascular reconstructive procedure is considered not to 
be possible: 
la. Persistent rest pain for at least 2 weeks, being treated with 
analgesics 
b. and/or ulceration organgrene offoot or toes. 
2a. Dropper ankle systolic pressure l ss than 50 mmHg or ankle 
brachial pressure index (ABPI) less than 35%. 
b. For patients with diabetes and incompressible vessels, leading 
to unreliable ankle pressure: absence ofarterial ankle 
pulsations. 
3. Patient informed consent. 
Exclusion criteria: 
1. Vascular disorders other than atherosderotic d sease. 
2. No rest pain (e.g. only intermittent claudication) and no 
ulceration or gangrene. 
3. Ankle pressure >50 mmHg or ABPI > 35%, when these 
pressures can be measured reliably. 
4. Palpable ankle pulsations inpatients with diabetes and 
incompressible vessels. 
5. Ulceration deeper than the fascia or with largest diameter 
> 3 cm. 
6. Infected, suppurating gangrene organgrene with largest 
diameter >3 cm. 
7. Intractable infection of ulceration ofgangrene. 
8. Critical ischaemia ofboth legs. 
9. Possibility of a meaningful vascular reconstruction. 
10. Neoplastic or other concomitant disease with a life 
expectancy < 1year. 
11. Presence ofa cardiac pacemaker. 
12. Impossibility oimplant an epidural electrode and stimulator. 
13. Previous participation in an ESES-trail or pilot study. 
14. Psychosocial ncompetence of the patient to satisfy the 
follow-up schedule. 
(Doppler ankle pressure, transcutaneous oximetr~ 
laser Doppler f luxmetr~ capillary microscopy). Prog- 
nostic factors for both primary and secondary out- 
comes will be studied. 
In a pilot study performed in 1989, 37 patients were 
randomised, 18 to conservative treatment, 19 to ESES. 
Amputation-free survival at 1 year was 67% in the 
ESES-treatment group versus 47% in the conservative 
group (p = 0.082) with a hazard ratio of 2.3. Based on 
the pilot-study and the available literature, the sample 
size of the trial was calculated using a hazard ratio of 
2 for amputation in the standard and ESES-treatment 
group. Assuming a total proportion of endpoints of 
50%, a two-sided confidence level (1-~) of 95% and 
power (1-t~) of 80%, at least 56 patients per treatment 
arm are required. 37 
Since November 1991, all patients with non-recon- 
structible critical limb ischaemia visiting vascular 
surgeons in participating centres were screened for 
eligibility for the ESES-trial. The planned progress 
through the study is outlined in Fig. 1. To evaluate the 
clinical course, the patients are followed up for at least 
18 months by the surgeon who enrolled the patient. 
The follow-up flow chart is shown in Fig. 2. Patients 
receiving ESES-treatment are checked regularly by a 
neurosurgeon or anaesthesiologist for the stimulation 
settings and possible technical or clinical complica- 
tions. The intake questionnaire concerning quality of 
life, pain and medical care is completed by the patient 
before randomisation. In addition to outpatient clinic 
follow-up, the coordination centre mails question- 
naires to the patient's home, 2-4 weeks after each 
follow-up visit; a postage-free reply envelope is 
provided. 
Organisation 
The coordination centre receives the patient-record 
forms and questionnaires and maintains a concurrent 
database. The study is set up as a multicentre trial 
with local responsibility. Within each clinic a centre- 
coordinator is responsible for the data collection. A 
steering and ethical committee supervise trial conduct 
and progress. Treatment allocation is performed in an 
independent Research Assistance Institute. The clilti- 
clan phones the randomisation centre, which checks 
eligibility, registers the patient and gives the treatment 
assignment right awa)~ using randomisation software 
on a personal computer. Stratified randomisation as 
described by Zelen 23 is used. Strata are formed by 
diabetes and institution, which ensures a balance of 
ESES- and standard treatment in diabetic and non- 
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diabetic patients and within the participating 
centres. 
Treatment regimes 
Patients allocated to standard treatment receive 
analgesics, antithrombotic and haemorrheologic 
Vascular surgeon judges, that for the patients with critical 
limb ischaemia no vascular reconstructive procedure is 
possible or beneficial 
Vascular surgeon explains the aim and procedures of
the study and obtains provisional patient consent 
Baseline assesment and evaluation of
elegibility criteria 
Written informed patient consent 
Randomisation 
Intervention 
Intake 
t=0 Randomisation 
Vascular surgeon Neurosurg. 
(standard and ESES) (ESES) 
Exam Qu Dop p,c Stim 
+ _+ _+ _+ + 
1 month + + + + 
3 months _+ + _+ + 
6 months + + + + 
12 months _+ + + + 
18 months +_ + _+ + 
end of study _+ + 
Coord. 
center 
Qu 
Abbreviations: 
+ = ESES treatment and standard treatment groups. 
+ = applies only to ESES treatment group. 
Exam = clinical examinations. 
Qu = questionnaire onquality of life, pain, medical 
consumption. 
Dop = Doppler ankle pressure measurements. 
~c = microcirculatory measurements. 
stim = follow-up stimulation settings by neurosurgeon r 
anaesthesiologists. 
Fig. 2. Flow chart of follow-up. 
drugs, local wound treatment and antibiotics, if 
indicated. There is a list of recommended medication, 
but no fixed treatment regimen. The clinician should 
in particular aim at adequate pain suppression. 
Sympathectomy and prostanoids were not excluded, 
but both were used infrequently. Those allocated to 
ESES treatment additionally receive an implantable 
spinal cord stimulation system (Itrel II® pulse gen- 
erator and quadripolar electrode, Medtronic). The lead 
is placed in the epidural space and manipulated until 
the patient experiences pleasant paraesthesia extend- 
ing down into the painful area of the limb. The pulse 
generator is implanted in the same session. Again, 
pr imary aim is adequate pain suppression. 
If pain suppression is inadequate, the effect is 
optimised by altering pain medication and/or  stim- 
ulation settings. In case of technical problems, elec- 
trode migration or infection, attempts are made to 
resolve the difficulties (by repositioning the electrode, 
replacing the implant or treating with antibiotics). If 
such problems cannot be corrected, the system is 
removed. These patients receive standard treatment, 
but are analysed in the original treatment group. 
Follow-up 
Fig. 1. Flow chart of patient progress through the ESES-trial. 
Progress 
Although estimated cautiously, the accrual rate turned 
out to be lower than expected. Randomisation of 120 
patients was completed in May 1994. There was quite 
some variation in the number  of recruited patients 
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among the clinics. Two hospitals provided over 30% of 
the patients. The intake rate is summarised in Fig. 3. 
A number of baseline patient characteristics are 
listed in Table 2. Prior to randomisation a mean of 2.2 
vascular interventions were performed in the critically 
ischaemic legs: none in 22%, one intervention i  23%, 
two interventions in 22%, three interventions in 13% 
and four or more interventions in 20% of the limbs. 
Forty patients (33%) previously had an ipsilateral 
sympathectomy. Mean ankle pressure in non-diabetic 
patients was 41.3 mmHg, (mean ankle-brachial pres- 
sure index was 0.26). 
Patient compliance on completing the question- 
naires on quality of life and consumption of medical 
care was most satisfactory. Completing the list took on 
average 47 rain (range 5-300 rnin). We compared the 
baseline quality of life score of the trial patients with 
reference values matched on age and sex, taken from a 
random sample of 2173 people representing the 
general English population. 24 The general well-being 
of trial patients proves to be much worse than that of 
the general population. Compared to other severely ill 
patients (liver and heart transplantation candidates), 
the quality of life is also less, pain being the pre- 
dominant characteristic. 2s'26 The results have been 
summarised in Fig. 4. 
By December 1994, 37 patients died and 53 patients 
underwent major amputation. The Kaplan-Meier plot 
is shown in Fig. 5. The incidence of death and 
amputation ishigh, indicating that a clinically relevant 
outcome improvement from ESES-treatment, if pre- 
sent, should be detectable. 
Discussion 
The need for controlled studies of promising new 
treatments in critical imb ischaemia has been stressed 
recently by many authors. 27-31 A number of con- 
troversies about he alleged effects of sympathectomy, 
prostanoids and epidural stimulation continue to exist 
as mainly uncontrolled reports are published. An 
adequate concurrent control group is mandator~ as a 
significant number of patients could be stable or 
improve with conservative methods. "Limb salvage" 
with conservative treatment could be as high as 
60%. 4,5"27'32 Furthermore, studies of new treatment 
modalities tend to coincide with considerably more 
medical care (hospitalised care, control visits), which 
in itself can cause better esults than expected. 
The primary question that needs to be answered, is 
whether ESES-treatment improves the subsequent 
health of a patient more than best medical treatment 
alone. This study compares the two treatment regimes 
under clinical practice conditions. The approach is 
thus pragmatic and aims at answering the question 
which mode of therapy works best, rather than how it 
works. B3 
120 
100 
8O 
N 60 
~ 3o 
20 
10 12 2 4 6 8 10 12 2 4 6 8 10 12 2 4 
91 I 92 I 93 I 94 
Time (months) 
Fig. 3. Accrual rate ESES-trial. 
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In non-reconstructible critical ischaemia, the effec- 
tiveness of treatment cannot be expressed in so-called 
"hard" endpoints only. Research reports in vascular 
surgery generally focus on mortality, limb survival 
and complications, whereas the patients' subjective 
feelings and quality of life are also important aspects 
of the patients' clinical condition, affecting the deci- 
sion whether or not to perform a therapeutical 
procedure. 34The ideal outcome would be the patients' 
health for his or her remaining life. In critical 
Table 2. Baseline characteristics on 120 patients enrolled in the 
ESES-trial 
Frequency % 
Male (mean age) 70 58 
Female (mean age) 50 42 
Diabetes 45 38 
Insulin dependent 19 16 
Rest pain 119 99 
Ischaemic skin lesions 77 64 
Contralateral limb: 
Asymptomatic 56 47 
Symptomatic 48 40 
Amputated 16 13 
Smoking: 
Never 37 31 
Stopped > 1 year 38 32 
Smoking 44 37 
Myocardial infarction i history 45 38 
Angina pectoris 26 22 
CVA 15 13 
TIA 18 15 
(70.6 years) 
(75.3 years) 
ischaemia limb salvage is an important endpoint, but 
only in combination with an acceptable level of pain 
and discomfort. 
In addition to the "true effects" of the treatments 
studied, there will be psychosomatic effects, analo- 
gous to placebo effects. Whereas in this study the 
psychosomatic effects can not be equalised between 
the two groups of patients (a nonfunctioning device 
should be implanted in patients with standard treat- 
ment, which is ethically unacceptable), we include 
these within the "true effects" and assess psychosocial 
effects as well. 33"34 To minimise the effect of follow-up 
visits and differences in data collection between ESES- 
and standard treatment, he measurement of quality of 
life and pain takes place between two follow-up 
visits. 
If the condition of the limb becomes progressively 
worse, the vascular surgeon has to decide whether to 
amputate. This decision is taken on grounds of 
progressive tissue loss, intractable infection or unbear- 
able pain. This is to some extent susceptible to 
individual judgement. Centre-specific factors are 
equalised by the stratified randomisation. Thus, defer- 
ral of amputation can be considered a positive result, 
if based on an improved condition of the extremity 
and on an improved health state, additionally taking 
into account he short life expectancy of the group of 
patients tudied. 
The eligibility criteria (Table 1) were drawn accord- 
100 
90 
80 
70 
60 
5~ 
~ 5o 
2:40  
30 
20 
10 
0 
Mobility 
• Trial 
Pain 
[ ]  Reference 
N 
Energy Sleep 
[ ]  Liver transplant 
Fig. 4. Quality of life, measured by Nottingham Health Profile, in trial patients (1st 
and to candidates on waiting lists for heart and liver transplantation (3rd/4th). 
states. 
Social Emotional 
[ ]  Heart ransplant 
column) as compared to a reference population (2nd) 
Higher scores correspond with deteriorating health 
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Fig. 5. Kaplan-Meier plot for the whole trial population, the upper 
line indicating mortality, the lower line indicating amputation. The 
area between the lines shows the proportion of patients alive with 
major amputation. The area below the lower line shows the 
proportion alive without amputation. At 365 days it can be read that 
76% of patients are alive: 41% without amputation and 35% with 
amputation. 
ing to the "European Consensus Document on 
Chronic Critical Limb Ischaemia". 4 Toe systolic pres- 
sures were not used, since a number of participating 
hospitals do not measure these. There has always been 
debate about the definition of critical limb ischaemia. 
This issue has become very prominent since Thomp- 
son et al. 35 presented ata on 148 severely ischaemic 
limbs in non-diabetic patients, presenting with rest 
pain, tissue necrosis or a combination of these. Ankle 
systolic pressure was > 50 mmHg in 51% of these 
limbs. A higher ankle pressure did not correspond 
with better prognosis. Therefore, many participating 
surgeons argued for reassessment of the ankle pres- 
sure restriction. From March 1993 onwards, patients 
with ankle pressures 50-70 mmHg (was < 50 mmHg) 
or ABPI 35-40% (was _<35%) were also included. 
Treatment allocation was balanced within this group 
by definition as a separate stratum. 
For comparability in research, the relevance of 
stringent definition of critical limb ischaemia is obvi- 
ous. However, the absence of a meaningful vascular 
(re)intervention means that this trial population is 
already different from the whole population of 
patients with critical imb ischaemia. Many patients in 
this trial have a history of multiple vascular recon- 
structions. Secondly, relaxation of some inclusion 
criterium may be necessary to ensure the feasibility of 
a multicentre trial and commitment of its partici- 
pants. 36 The essential feature is that the trial is 
representative for the patient group likely to benefit 
from its findings. Efficacy and safety as regards to 
clinical outcome will be analysed according to the 
intention-to-treat principle. Consequently, all eligible 
patients, regardless of technical problems or com- 
pliance, are included in the analysis. This results in a 
valid comparison as it relates to actual clinical 
practice. 36 
Since ESES-treatment involves a costly implant, 
but might decrease the expense of amputation and 
rehabilitation, the issue of cost versus possible benefit 
has often been addressed. 16'17"29 A concrete analysis 
of cost, however, has never been performed. Costs 
can be classified into direct medical costs (inside and 
outside the hospital), direct non-medical costs (patient 
costs) and indirect cost. 3s The viewpoint of the 
analysis has to be the society perspective, thus 
all costs and consequences will be taken into account 
whomsoever they accrue. The costs are calculated 
per patient as the product of volumes and market 
prices. Volumes will be determined for all patients, 
while cost per procedure will be estimated in a smaller 
sample. 
For valuation of the cost, we first identified the 
fundamental cost items. A detailed cost analysis is 
necessary to estimate market prices for the important 
determinants, i.e. those with large volumes or high 
prices. These are primarily direct medical costs, such 
as in-hospital-sta~ Operative procedures (implanta- 
tion, amputation), outpatient visits, and admission to 
nursing-home or rehabilitation centre. Prices are val- 
ued using department based cost registrations and 
involve quantification of attendance by health pro- 
fessionals, suppies, equipment, and capital costs in 
one university hospital and two general hospitals. 
Prices of admission to a nursing-home or rehabilita- 
tion clinic are available from a Dutch national inves- 
tigation. For less important cost items, as travel 
expenses and out-of-pocket payments, charges or 
expert estimates are used as approximations of the 
market prices. Finally, the various medical effects 
(outcome measures as patient- and limb survival and 
quality of life) will be related to the cost of each 
treatment. This cost-effectiveness analysis will be 
performed for the whole group of trial patients, but 
also for specific patient profiles. If the most effective 
treatment is also the most expensive, the ratio of cost 
and effects may need to be compared with other 
health programs. 
In short, this randomised clinical trial will provide 
insight in the effects of ESES treatment in patients with 
non-reconstructible critical limb ischaemia. Intake of 
120 patients is completed and follow-up is proceeding 
adequately. The results of this study will be ready for 
presentation and publication at the end of 1995. 
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Appendix 
The ESES study group: 
Academisch Ziekenhuis Groningen: J.J.A.M. van den 
Dungen, M.J. Staal; Medisch Spectrum Twente, 
Enschede: R.J. van Det, H.E. van de Aa; Ziekenhuis 
De Weezenlanden, Zwolle: E.A. Kole; St. Antonius 
Ziekenhuis, Nieuwegein: EL. Moll, E. Scholten, A.L. 
Liem; Medisch Centrum Alkmaar, Alkrnaar: H.A. van 
Dijk, EJ. Theuvenet; Ziekenhuis Leyenburg, Den 
Haag: J.C. Sier, N. Lambooy; St. Clara Ziekenhuis, 
Rotterdam: T.I. Yo, G. Kazemier; St. Franciscus Gas- 
thuis, Rotterdam: C.H.A. Wittens; Academisch Zie- 
kenhuis Rotterdam-Dijkzigt: N.A.J.J. duBois, H. van 
Urk, A.I. Veeger; Catharina Ziekenhuis, Eindhoven: J. 
Buth; De Wever Ziekenhuis, Heerlen: E.C.M. Bollen, 
H.EJ.K.M. van Houtte, J. Lens; Maasland Ziekenhuis, 
Sittard: A.G.M. I-Ioofwijk; Academisch Ziekenhuis 
Maastricht: J.H.M. Tordoir, EJ.E.H.M. Kitslaar; Zie- 
kenhuis Lievensberg, Bergen op Zoom: T.H.A. Bik- 
kers; Deventer Ziekenhuizen-St. Geertruiden, Deven- 
ter: D. van Lent, EJ. van Elk; Academisch Medisch 
Centrum, Amsterdam: M.J.H.M. Jacobs, D.Th. 
Ubbink; Ziekenhuis St. Jansdal, Harderwijk: A.C. van 
der Ham. 
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